复方红豆杉胶囊联合BEV、TC化疗对复发性卵巢癌患者的效果观察

Effect of compound Taxus capsule combined with BEV and TC chemotherapy in patients with recurrent ovarian cancer

目的观察复方红豆杉胶囊联合贝伐珠单抗(BEV)、紫杉醇^+卡铂(TC)化疗对复发性卵巢癌患者的效果。方法选取82例复发性卵巢癌患者按SAS 5.0软件生成的随机数字表分为两组。所选患者均予以BEV、TC化疗,观察组同时予以复方红豆杉胶囊。对比两组患者疗效,治疗前后肿瘤标志物水平、T细胞免疫指标变化及不良反应;随访12个月,对比治疗后6个月、12个月生存率。结果观察组总有效率为80.49%,高于对照组的58.54%;治疗后两组肿瘤标志物水平均下降,观察组肿瘤标志物水平均低于对照组;对照组CD3^+、CD4^+、CD4^+/CD8^+水平下降,且观察组CD3^+、CD4^+、CD4^+/CD8^+水平均高于对照组;观察组治疗后12个月生存率为75.61%,对照组为51.22%,观察组高于对照组;上述差异均有统计学意义(P<0.05);观察组恶心/呕吐、脱发、骨髓抑制发生率、治疗后6个月生存率分别为43.90%、29.27%、17.07%、90.24%,对照组分别为48.78%、24.39%、21.95%、82.93%,对比差异均无统计学意义(P>0.05)。结论对复发性卵巢癌患者采用复方红豆杉胶囊联合BEV、TC化疗可增强疗效,控制肿瘤标志物水平,避免细胞免疫力下降,使用安全,还可提升生存率。

Objective To observe the effect of compound Taxus capsule combined with Bevacizumab(BEV)and Taxol^+Carboplatin(TC)chemotherapy on patients with recurrent ovarian cancer.Methods 82 patients with recurrent ovarian cancer were divided into two groups according to the random number table generated by SAS 5.0 software.All the selected patients received BEV and TC chemotherapy,and the observation group was also given compound Taxus capsule.The efficacy of patients in the two groups,tumor marker levels,T cell immune index changes and adverse reactions before and after treatment were compared;Patients were followed up for 12 months and the survival rates were compared at 6 months and 12 months after treatment.Results The total effective rate was 80.49%in the observation group,higher than 58.54%in the control group.After treatment,the level of tumor markers in both groups decreased,and that in the observation group was lower than that in the control group.The levels of CD3^+,CD4^+and CD4^+/CD8^+in the control group decreased,and the levels of CD3^+,CD4^+and CD4^+/CD8^+in the observation group were all higher than those in the control group.The 12-month survival rate was 75.61%in the observation group and 51.22%in the control group,which was higher than that in the control group.The above differences were statistically significant(P<0.05).The incidence of nausea/vomiting,hair loss,bone marrow suppression,and 6-month survival rates after treatment were 43.90%,29.27%,17.07%,and 90.24%in the observation group,and 48.78%,24.39%,21.95%,and 82.93%in the control group,respectively,with no statistically significant differences(P>0.05).Conclusion For patients with recurrent ovarian cancer,compound Taxus capsule combined with BEV and TC chemotherapy can enhance the efficacy,control the level of tumor markers,avoid the decline of cellular immunity,be safe to use,and can also improve the survival rate.